Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia
作者： Emmanuelle Sarlon , Pierre Morange , Pierre Suchon , Gabrielle Sarlon-Bartoli , Raphael Soler
DOI: 10.1016/J.JDMV.2021.02.002
关键词: Asymptomatic 、 Internal medicine 、 Echogenicity 、 Ultrasound 、 Lesion 、 Complication 、 Occlusion 、 Stenosis 、 Nilotinib 、 Cardiology 、 Medicine
摘要: Summary Introduction Patients exposed to nilotinib for chronic myeloid leukemia (CML) appear be at risk of arterial complication. The prevalence and aspect ultrasound asymptomatic lesions are unknown. Objective To describe characteristics anomalies in patients treated with CML. Methods from 2006 2015 the department Paoli-Calmettes Institute, Marseille, were included retrospectively. A vascular screening was carried out 2010. first examination described: plaque its echogenicity, stenosis or occlusion. anomaly (VAA) defined by presence a clinical and/or anomaly. without VAA initial compared using bivariate multivariate analysis. Results 74 (51.4% men, mean age 54.5 years); 25 had (33.8%). Carotid bulb most involved territory (44%). Arterial were: 88% plaques, 44% > 50% 12% 72.7% plaques echolucent hypoechogenic. present evaluation baseline significantly older (64.9 vs 49.3, P Conclusion Nilotinib seems associated unstable lipid-like appearance. carotid common lesion hypoechogenic plaque. can occur cardiovascular factors. This result encourages us systematically screen follow all even those
sci-hub.st 参考文章(23)
Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla, Javier Pinilla-Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Timothy P. Hughes, Giovanni Martinelli, Dong-Wook Kim, Yaping Shou, Neil J. Gallagher, Rick Blakesley, Michele Baccarani, Jorge Cortes, Philipp D. le Coutre, Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results Blood. ,vol. 117, pp. 1141- 1145 ,(2011) , 10.1182/BLOOD-2010-03-277152
F J Giles, M J Mauro, F Hong, C-E Ortmann, C McNeill, R C Woodman, A Hochhaus, P D le Coutre, G Saglio, Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis Leukemia. ,vol. 27, pp. 1310- 1315 ,(2013) , 10.1038/LEU.2013.69
Peter Valent, Emir Hadzijusufovic, Gerit-Holger Schernthaner, Dominik Wolf, Delphine Rea, Philipp le Coutre, Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors Blood. ,vol. 125, pp. 901- 906 ,(2015) , 10.1182/BLOOD-2014-09-594432
Karl J. Aichberger, Susanne Herndlhofer, Gerit-Holger Schernthaner, Martin Schillinger, Gerlinde Mitterbauer-Hohendanner, Christian Sillaber, Peter Valent, Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML American Journal of Hematology. ,vol. 86, pp. 533- 539 ,(2011) , 10.1002/AJH.22037
Elias J. Jabbour, Jorge E. Cortes, Hagop M. Kantarjian, Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options Clinical Lymphoma, Myeloma & Leukemia. ,vol. 13, pp. 515- 529 ,(2013) , 10.1016/J.CLML.2013.03.018
Marie Stève-Dumont, Bernadette Baldin, Laurence Legros, Antoine Thyss, Daniel Re, Fanny Rocher, Florian Ajmia, Anne Spreux, Milou-Daniel Drici, Are nilotinib-associated vascular adverse events an under-estimated problem? Fundamental & Clinical Pharmacology. ,vol. 29, pp. 204- 208 ,(2015) , 10.1111/FCP.12102
T D Kim, D Rea, M Schwarz, P Grille, F E Nicolini, G Rosti, L Levato, F J Giles, H Dombret, T Mirault, H Labussière, R Lindhorst, W Haverkamp, I Buschmann, B Dörken, P D le Coutre, Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib Leukemia. ,vol. 27, pp. 1316- 1321 ,(2013) , 10.1038/LEU.2013.70
Tristan Mirault, Delphine Rea, Arshid Azarine, Emmanuel Messas, Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome. European Journal of Haematology. ,vol. 94, pp. 363- 367 ,(2015) , 10.1111/EJH.12367
Herbert C. Stary, A. Bleakley Chandler, Robert E. Dinsmore, Valentin Fuster, Seymour Glagov, William Insull, Michael E. Rosenfeld, Colin J. Schwartz, William D. Wagner, Robert W. Wissler, A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis A Report From the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association Circulation. ,vol. 92, pp. 1355- 1374 ,(1995) , 10.1161/01.CIR.92.5.1355
Ajay Gupta, Kartik Kesavabhotla, Hediyeh Baradaran, Hooman Kamel, Ankur Pandya, Ashley E. Giambrone, Drew Wright, Kevin J. Pain, Edward E. Mtui, Jasjit S. Suri, Pina C. Sanelli, Alvin I. Mushlin, Plaque Echolucency and Stroke Risk in Asymptomatic Carotid Stenosis Stroke. ,vol. 46, pp. 91- 97 ,(2015) , 10.1161/STROKEAHA.114.006091